Newborn screening for cystic fibrosis

Area of Science:

• Medical research
• Genetics
• Pediatrics

Background:

• Cystic Fibrosis (CF) is a genetic disorder affecting multiple organs.
• Newborn screening aims to detect CF early for timely intervention.
• The impact of newborn screening on long-term CF outcomes remains a key research question.

Purpose of the Study:

• To evaluate if newborn screening for CF improves clinical outcomes, quality of life, and survival.
• To assess if screening prevents or reduces irreversible organ damage in individuals with CF.
• To determine any adverse effects associated with newborn CF screening.

Main Methods:

• Systematic review of randomized or quasi-randomized controlled trials comparing CF screening to clinical diagnosis.
• Searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
• Two independent authors assessed trial eligibility, quality, and extracted data.

Main Results:

• Two trials involving over 1.1 million neonates were eligible; data from one study were analyzed.
• Screened participants showed reduced severe malnutrition and better weight/height percentiles.
• Early pulmonary function and chest radiograph scores were better in screened infants, but long-term outcomes were confounded.
• Earlier colonization with Pseudomonas aeruginosa was observed in screened individuals.

Conclusions:

• Newborn screening for CF demonstrates nutritional benefits and potential for improved pulmonary outcomes.
• Confounding factors significantly influenced long-term pulmonary prognosis in individuals with CF.
• Newborn screening for CF appears to be more cost-effective than traditional diagnosis.